ERBB2 and breast carcinoma: HER2 + breast cancer is highly aggressive and prone to adverse clinical outcomes with short survival and poor prognosis [5], so it is more critical to predict at an early stage and take therapeutic measures for the possible prognostic outcome of patients such as drug therapy such as pyrrolizumab, trastuzumab or neoadjuvant chemotherapy (NAC) [6, 7].